<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02544217</url>
  </required_header>
  <id_info>
    <org_study_id>KH176-101</org_study_id>
    <nct_id>NCT02544217</nct_id>
  </id_info>
  <brief_title>A Dose-escalating Clinical Trial With KH176</brief_title>
  <official_title>A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Clinical Trial With KH176</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Khondrion BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Drug Research Unit Ghent, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Khondrion BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mitochondrial Diseases are rare progressive, multi-system, often early fatal disorders
      affecting both children and adults. KH176 is a novel chemical entity currently under
      development for the treatment of inherited mitochondrial diseases, including MELAS
      (Mitochondrial Encephalomyopathy, Lactic acidosis, and Stroke-like episodes), Leigh's Disease
      and LHON (Leber's Hereditary Optic Neuropathy). KH176 is a potent intracellular redox
      modulating agent targeting the reactive oxygen species which are important in the
      pathogenesis of disorders of mitochondrial oxidative phosphorylation. After demonstrating a
      favourable safety profile in the pre-clinical testing, the safety, tolerability and
      pharmacokinetic and pharmacodynamic characteristics of the compound will now be evaluated in
      healthy male subjects in this trial
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability (assessment of adverse events, routine clinical laboratory, vital signs, ECG, physical exam)</measure>
    <time_frame>4 months</time_frame>
    <description>assessment of adverse events, routine clinical laboratory, vital signs, ECG, physical exam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of KH176</measure>
    <time_frame>7 days</time_frame>
    <description>assessment of time to reach peak plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of KH176</measure>
    <time_frame>7 days</time_frame>
    <description>assessment of peak plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of KH176</measure>
    <time_frame>7 days</time_frame>
    <description>assessment of the area under the plasma concentration versus time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of KH176</measure>
    <time_frame>7 days</time_frame>
    <description>assessment of half life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of KH176</measure>
    <time_frame>7 days</time_frame>
    <description>change from baseline in biochemistry related to OXPHOS (glutathione, lactate)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>MELAS</condition>
  <condition>LHON</condition>
  <condition>Leigh Syndrome</condition>
  <condition>Mitochondrial Disease</condition>
  <condition>Mitochondrial DNA tRNALeu(UUR) m.3243A&lt;G Mutation</condition>
  <arm_group>
    <arm_group_label>Single Escalating</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 alternating groups receiving escalating single doses of active/placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Escalating</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 multiple escalating groups, receiving active/placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KH176</intervention_name>
    <arm_group_label>Single Escalating</arm_group_label>
    <arm_group_label>Multiple Escalating</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Single Escalating</arm_group_label>
    <arm_group_label>Multiple Escalating</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy as assessed by medical history, physical examination, Vital Signs, Clinical
             Laboratory, ECG

        Exclusion Criteria:

          -  Allergies,

          -  Concomitant medication,

          -  concomitant disease,

          -  relevant surgery,

          -  recent blood donation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Drug Research Unit Ghent</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2015</study_first_submitted>
  <study_first_submitted_qc>September 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2015</study_first_posted>
  <last_update_submitted>February 5, 2016</last_update_submitted>
  <last_update_submitted_qc>February 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitochondrial Diseases</mesh_term>
    <mesh_term>Leigh Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

